EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Onabotulinum Toxin A-Led Urinary Tract Infections—Should we Safeguard? A Randomized Controlled Trial

Anastasiya Holubyeva iD, Kaythi Khin, Tess Gao, Shaun Adair, Erika Wasenda, Laura Dhariwal, Ricardo Caraballo, Svjetlana Lozo, John Rutledge, Carolyn Botros

International Urogynecology Journal · 2025

DOI: 10.1007/s00192-024-06028-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Urogynecology Journal, 2025. Verfasst von Anastasiya Holubyeva und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urogynecology and Reconstructive Pelvic Surgery, Atlantic Health System, 435 South Street, Suite 370, Morristown, NJ, 07960, USA. a.hol…. Hauptthemen laut MEDLINE: Urinary Tract Infections, Botulinum Toxins, Type A, Urinary Bladder, Overactive, Antibiotic Prophylaxis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND HYPOTHESIS: The objective of our study was to evaluate the need for antibiotic prophylaxis for urinary tract infection (UTI) prevention before Onabotulinum toxin A injection for overactive bladder (OAB). We hypothesize that the lack of antibiotic prophylaxis might not be inferior to administering prophylaxis. METHODS: This was a multi-centered, nonblinded, randomized controlled trial conducted between August 2022 and September 2024. Participants were randomized to either receive oral antibiotics or no treatment. Our primary outcome was to measure the rate of UTI at 2 weeks. Our secondary outcomes included post-void residuals, assessment for antibiotic compliance, and UTI rates at 6 weeks. Given a 20% UTI rate and a delta of 20%, 64 participants per study arm were necessary to achieve 80% power with an alpha value of 0.05. RESULTS: Rates of UTI at 2 weeks post-procedure were 9.2% in the antibiotics group and 10.9% in the control group (p = 0.75). UTI rates 6 weeks post-procedure were 4.7% in the antibiotics group and 11.1% in the control group (p = 0.21). When analyzing variables such as age, race, body mass index, menopause status, vaginal estrogen use, or the rates of positive pre-procedure urine cultures, no factors proved to be predictors of developing a UTI at 2 weeks post-procedure. The urinary retention rate in our study was 0.8%. CONCLUSIONS: Rates of UTI were not significantly different between patients who obtained antibiotics prophylaxis and those who did not at 2 and 6 weeks following injection. Foregoing antibiotics prophylaxis in order to safeguard from the dangers of antimicrobial resistance may be considered in the treatment of OAB with Onabotulinum toxin A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsBotulinum Toxins, Type AUrinary Bladder, OveractiveAntibiotic ProphylaxisAnti-Bacterial AgentsHumansFemaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

Antibiotics resistanceOnabotulinum toxin AOveractive bladderUrinary tract infections

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin AAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Urogynecology and Reconstructive Pelvic Surgery, Atlantic Health System, 435 South Street, Suite 370, Morristown, NJ, 07960, USA. a.holubyeva@gmail.com.
  • Department of Urogynecology and Reconstructive Pelvic Surgery, Atlantic Health System, 435 South Street, Suite 370, Morristown, NJ, 07960, USA.
  • Department of Urogynecology and Reconstructive Pelvic Surgery, Columbia University, New York, NY, USA.
  • Department of Biostatistics, Atlantic Center for Research, Morristown, NJ, USA.

ORCID-Profile: Anastasiya Holubyeva

Zitieren

APA

Holubyeva, A., Khin, K., Gao, T., Adair, S., Wasenda, E., Dhariwal, L., Caraballo, R., Lozo, S., Rutledge, J., & Botros, C. (2025). Onabotulinum Toxin A-Led Urinary Tract Infections—Should we Safeguard? A Randomized Controlled Trial. International Urogynecology Journal. https://doi.org/10.1007/s00192-024-06028-3

Vancouver

Holubyeva A, Khin K, Gao T, Adair S, Wasenda E, Dhariwal L, et al. Onabotulinum Toxin A-Led Urinary Tract Infections—Should we Safeguard? A Randomized Controlled Trial. International Urogynecology Journal. 2025. doi:10.1007/s00192-024-06028-3

BibTeX
@article{Holubyeva2025,
  author = {Holubyeva, Anastasiya and Khin, Kaythi and Gao, Tess and Adair, Shaun and Wasenda, Erika and Dhariwal, Laura and Caraballo, Ricardo and Lozo, Svjetlana and Rutledge, John and Botros, Carolyn},
  title = {Onabotulinum Toxin A-Led Urinary Tract Infections—Should we Safeguard? A Randomized Controlled Trial},
  journal = {International Urogynecology Journal},
  year = {2025},
  doi = {10.1007/s00192-024-06028-3}
}
Kostenlos starten →